ORBIMED ADVISORS LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+1,327,140
(19.5%)
New positions
18
Sold out positions
10
Turnover %
8.2%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INTERCEPT PHARMACEUTICALS, INC. | 453,703 | 383.0% |
| OVERSEAS SHIPHOLDING GROUP INC | 195,598 | 227.2% |
| PRGO | 163,445 | NEW |
| ISRG | 118,682 | 414.8% |
| INTERMUNE INC | 85,836 | 75.7% |
| EXPRESS SCRIPTS HLDG CO | 67,065 | 74.2% |
| NBIX | 63,187 | 257.1% |
| RELYPSA INC | 47,819 | 19.2% |
| ABBV | 47,788 | 24.1% |
| MCK | 44,937 | 78.4% |
Top Reduces (Value $000, Stocks/ETFs)
| PERRIGO CO PLC F | -118,625 | -100.0% |
| CELG | -105,447 | -35.5% |
| AETNA INC NEW | -75,740 | -94.1% |
| UNH | -51,199 | -86.0% |
| EXEL | -47,331 | -82.2% |
| QGEN | -45,882 | -100.0% |
| REGN | -41,496 | -20.4% |
| WELLPOINT INC | -39,635 | -100.0% |
| INCY | -38,817 | -18.8% |
| EXAS | -31,800 | -54.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
274,063
(3.4% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|